Healthcare
Contineum Therapeutics, Inc. Class A Common Stock(CTNM)
Live Price
Offline$11.94
-1.81% today
1Y Change
+164.92%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $540.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +0.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Healthcare stock with a market cap of $540.00M and listed on NASDAQ. The stock last traded around $11.94 and up 164.9% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +0.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +0.5%, free cash flow -66.5% with operating margin 0.0% and ROIC -26.0%. Stock Foundry combines CTNM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +0.5%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.4% | -5.4% | -16.2% |
2026 Mar 5, 2026 | +2.0% | +0.5% | +0.4% | -2.7% |
2025 Oct 30, 2025 | +22.4% | +4.5% | +4.5% | +5.0% |
Benchmark Edge
CTNM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CTNM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CTNM Max Drawdown
-29.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CTNM and SPY.
Company Overview
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ
Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Its primary function lies in advancing novel drug candidates aimed at addressing unmet medical needs within the healthcare sector. The company emphasizes research and development, with a focus on diseases that currently lack effective treatment options, potentially impacting various medical fields such as oncology, neurology, and autoimmune disorders. Continua Therapeutics Inc. is significant in the market due to its commitment to pioneering next-generation pharmaceuticals that could redefine standard treatment protocols. Through strategic collaborations and a robust pipeline of research projects, the company plays a critical role in the biotech industry, pushing the boundaries of medical science.
- Leadership
- Mr. Carmine N. Stengone MBA, MS
- Employees
- 51
- Street Address
- 3565 General Atomics Court, Suite 200
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.1
Growth
- Revenue
- 0.0%
- EPS
- +0.5%
- Free Cash Flow
- -66.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -27.1%
- ROIC
- -26.0%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 38.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.